SMS Cell-Derived ECM for Human Vessel Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing endothelial cell reorganization and differentiation to form micro- and macrovessel structures are inefficient and often rely on murine-sourced extracellular matrices that do not fully recapitulate human ECM, posing issues for clinical applications and sensitive stem cell or cancer conditions.
Innovation Solution
The use of an extracellular matrix derived from small mobile stem (SMS) cells, which is contacted with a substrate in the presence of endothelial cells to induce rapid and efficient reorganization and differentiation, allowing for the formation of tubule structures and vessel networks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If murine-sourced ECM preparations are used to induce endothelial cell reorganization and differentiation, then vessel formation can be achieved, but the process is inefficient and does not fully recapitulate human ECM
Solution Approach 1:
The patent changes the source parameter of the ECM from murine (EHS mouse sarcoma cells) to human (SMS cells), thereby improving the biological relevance and reliability for human applications. This parameter change resolves the contradiction by using human-derived ECM that fully recapitulates human ECM composition and function, while still achieving efficient vessel formation through the optimized combination of human ECM with endothelial cells and substrates.
2Reliability
If traditional ECM preparations are used for endothelial cell culture, then tube structures can form within 1 week to 6-12 weeks, but the process is time-consuming and slow
Solution Approach 1:
The patent applies preliminary action by pre-coating the culture substrate with human SMS cell-derived ECM before introducing endothelial cells. This pre-preparation of the ECM environment creates an optimal conditions that significantly accelerates tube formation, reducing the culture time from weeks to days while maintaining reliable tube structure formation. The preliminary ECM coating ensures immediate cell adhesion and rapid differentiation.
3Productivity
If murine ECM is used for clinical applications or sensitive stem cell/cancer conditions, then vessel formation assays can be performed, but issues arise due to species differences and contamination risks
Solution Approach 1:
The patent extracts the ECM component from murine sources and replaces it with human SMS cell-derived ECM. This extraction and replacement eliminates the harmful effects of species mismatch and potential contamination risks associated with murine products. The human-derived ECM maintains full functionality for vessel formation assays while being biologically compatible with human cells, stem cells, and cancer models, thereby removing the harmful factors without sacrificing assay performance.
Data Source
AI summary
Disclosed herein are methods of inducing endothelial cell reorganization or differentiation to form micro- and macrovessel structures using an extracellular matrix, such as one derived from small mobile stem (SMS) cells, and a substrate, which can also be coated in molecules or otherwise physically manipulated to cause localized effects on reorganization Also disclosed is a kit implementation for performing endothelial cell reorganization.